BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene to Rebrand as BeOne Medicines With Oncology-Focused New Nasdaq Ticker "ONC"
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to "ONC" on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.
百濟神州有限公司（納斯達克：BGNE，香港交易所：06160，上海證券交易所：688235），一家全球腫瘤學公司，計劃將其名稱更改爲BeOne Medicines Ltd.，並宣佈將於2025年1月2日更改其納斯達克標的爲"ONC"，這反映了其長期致力於全球提供創新腫瘤藥物的承諾。
"As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere."
百濟神州聯合創始人、董事長兼首席執行官約翰·沃伊勒說："在我們踏入第15個年頭之際，將我們的標的更改爲ONC反映了我們在腫瘤學領域的堅定領導承諾，以及向全球癌症患者提供變革性藥物的使命。" "這一里程碑讓我們爲所取得的成就感到驕傲，並激發我們對未來的期待，推動我們推進創新的血液學事業和實體腫瘤管道，爲每一位患者帶來實質性影響。"
The Company's CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change. No action by the Company's shareholders is required to implement the Nasdaq ticker symbol change.
公司的CUSIP號碼將保持不變。此外，公司在香港交易所和上海證券交易所科創板的股票代碼和股票名稱也將保持不變。公司的股東不需要採取任何行動來實施納斯達克標的變更。
